Exin Therapeutics
Last verified 2026-09-25. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $1.0Mattributed |
|---|---|
| Latest round | seed, $1.0M, 2025-01-01attributed |
| Founded | 2024 |
| Headquarters | San Francisco, USA |
| Industry | healthtech |
| Stage | seed |
| Website | exintherapeutics.com |
Clinical-stage biotech developing genetic medicines for inherited metabolic disorders. Built around partnered or wholly-owned drug pipeline. Differentiates on novel exon-skipping or splice-modulating constructs.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-01-01 | seed | $1.0M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $1.0M | attributed | yc named as publisher. No document URL on file. |
| Total raised $1.0M | attributed | yc named as publisher. No document URL on file. |
| Company existence | sourced | Y Combinator named as publisher. Document, retrieved 2026-09-17. |
| Description | self-reported | exintherapeutics.com, read 2026-09-25 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-24Existence: self-reported → sourced, Y Combinator, document, retrieved 2026-09-17 | Existence | self-reported → sourced | Y Combinator, document, retrieved 2026-09-17 |
Records begin 2026-09-24. All changes